SCHEMBL752665

SCHEMBL752665

CCOC(=O)CCc1ccc(N)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.72
CYP4A11 Q02928 2/20 0.72
CYP4Z1 Q86W10 3/20 0.56
PPIB P23284 1/20 0.55
PPIA P62937 1/20 0.55
PPID Q08752 1/20 0.55
PPIG Q13427 1/20 0.55
LMNA P02545 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
MAOA P21397 1/20 0.53
TDP1 Q9NUW8 2/20 0.50
HRH3 Q9Y5N1 1/20 0.48
CYP4F11 Q9HBI6 1/20 0.47
CYP4F12 Q9HCS2 1/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HTT P42858 1/20 0.47
PPARG P37231 1/20 0.46
EPHX2 P34913 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6982675 0.98 CYP4F2 (0.70) CYP4F2CYP4A11CYP4Z1PPIBPPIA
SCHEMBL3133486 0.92 CYP4F2 (0.62) CYP4F2CYP4A11CYP4Z1PPIBPPIA
SCHEMBL68902 0.91 CYP4F2 (0.85) CYP4F2CYP4A11CYP4Z1LMNATDP1
SCHEMBL1467579 0.90 CYP4F2 (0.58) CYP4F2CYP4A11CYP4Z1PPIBPPIA
SCHEMBL8819359 0.89 CYP4F2 (0.72) CYP4F2CYP4A11CYP4Z1LMNACYP1A2
Hydrochloric Acid SCHEMBL27741536 0.88 CYP4Z1 (0.57) CYP4F2CYP4A11CYP4Z1PPIBPPIA
SCHEMBL9744594 0.88 CYP4Z1 (0.59) CYP4F2CYP4A11CYP4Z1PPIBPPIA
Hydrochloric Acid SCHEMBL11113065 0.88 CYP4F2 (0.70) CYP4F2CYP4A11CYP4Z1CYP1A2TDP1
SCHEMBL16264858 0.87 CYP4Z1 (0.58) CYP4F2CYP4A11CYP4Z1PPIBPPIA
Hydrochloric Acid SCHEMBL27344081 0.87 CYP4Z1 (0.58) CYP4F2CYP4A11CYP4Z1PPIBPPIA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111646911-A Method for synthesizing o-aminoacetophenone 广东莱佛士制药技术有限公司 2020-09-11 CN disclosed
US-20200148937-A1 INHIBITING HYDROCARBON HYDRATE AGGLOMERATION COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2020-05-14 US disclosed
EP-2956444-B1 POSACONAZOLE IMMUNOASSAYS ARK DIAGNOSTICS INC (US) 2018-05-30 EP disclosed
EP-2956444-B1 POSACONAZOLE IMMUNOASSAYS ARK DIAGNOSTICS INC (US) 2018-05-30 EP disclosed
US-9920136-B2 Posaconazole immunoassays ARK DIAGNOSTICS, INC. (US) 2018-03-20 US disclosed
US-9920136-B2 Posaconazole immunoassays ARK DIAGNOSTICS, INC. (US) 2018-03-20 US disclosed
US-9920136-B2 Posaconazole immunoassays ARK DIAGNOSTICS, INC. (US) 2018-03-20 US disclosed
CN-107176922-A A kind of synthetic method of quinoline 湖南华腾制药有限公司 2017-09-19 CN disclosed
EP-2956444-A1 POSACONAZOLE IMMUNOASSAYS ARK Diagnostics, Inc. (US) 2015-12-23 EP disclosed
EP-2942349-A1 ENZYME MODULATORS AND TREATMENTS Deciphera Pharmaceuticals, LLC (US) 2015-11-11 EP disclosed
EP-0052296-A1 Glutamine derivatives usable for curing immune diseases, methods for their preparation and compositions comprising said derivatives MITSUBISHI KASEI CORPORATION (JP) 1982-05-26 EP disclosed
US-4318914-A Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds AMERICAN CYANAMID COMPANY (US) 1982-03-09 US disclosed
US-4310545-A Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds AMERICAN CYANAMID COMPANY (US) 1982-01-12 US disclosed
US-4305959-A Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds AMERICAN CYANAMID COMPANY (US) 1981-12-15 US disclosed
US-4281019-A 4-[(Unsaturated or cyclopropylated alkyl)amino]phenyl compounds useful as hypolipidemic and antiatherosclerotic agents AMERICAN CYANAMID COMPANY (US) 1981-07-28 US disclosed
US-4259352-A 4-[Cycloalkyl- or cycloalkenyl-amino(cycloalkyl- or cycloalkenyl-alkenyl)amino]phenyl compounds, useful as hypolipidemic and antiatherosclerotic agents AMERICAN CYANAMID COMPANY (US) 1981-03-31 US disclosed
US-4211783-A Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds AMERICAN CYANAMID COMPANY (US) 1980-07-08 US disclosed
US-4205085-A Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds AMERICAN CYANAMID COMPANY (US) 1980-05-27 US disclosed
EP-0003663-A2 Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them AMERICAN CYANAMID COMPANY (US) 1979-08-22 EP disclosed
US-4113871-A HYPOGLYCEMICALLY AND HYPOLIPIDEMICALLY ACTIVE DERIVATIVES OF PHENYL-ALKANE-CARBOXYLIC ACIDS BOEHRINGER MANNHEIM GMBH (DE) 1978-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200148937-A1 INHIBITING HYDROCARBON HYDRATE AGGLOMERATION H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AHR, SHH CYP4F2 914/4885CYP4A11 776/4885CYP4Z1 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.